German life sciences group Sartorius will leverage its local roots and global network to better support Chinese biotech firms in their quest to bring innovative therapies to the global market, said a senior executive of the company.

This will help transform China's new drug ambitions into global medical realities, accelerating the development and production of breakthrough therapies from China to benefit patients worldwide, said Wang Xuyu, general manager of Sartorius China, during a media interview on Thursday.

Sartorius, which currently serves a wide array of Chinese biopharmaceutical enterprises, vaccine producers, and academic and research laboratories, joined hands with the Shanghai Biopharmaceutics Industry Association to hold a summit in Shanghai on the same day as part of a series of events to mark the company's 30 years of operations in the Chinese market.

"As a leading partner in life sciences research and the biopharmaceutical industry, Sartorius can support its partners in addressing market entry challenges across different regions with its globally unified high standards and comprehensive, reliable process systems. Also, its worldwide production and service network establishes a resilient supply chain that ensures the global accessibility of innovative medicines from China," said Wang.

"This allows it to be not just a technology enabler but also a strategic partner, committed to walking alongside its Chinese partners as they venture onto the global stage," she said.

With a 155-year history, Sartorius has witnessed robust growth in its operations in the Asia-Pacific in recent years, with China playing a pivotal role.

Market research data predicted that the global biopharmaceutical sector will maintain low double-digit growth from now into the future, with the diversity of biomolecules becoming even more varied.

The Chinese market will also be diverse, with increasingly varied and complex demands for biotechnology, said Wang.

"We are committed to collaborating with our clients to develop innovative solutions and produce more affordable biopharmaceuticals that meet patient needs," she said.